Aptus Pharma Ltd vs Cipla Ltd
A side-by-side comparison of Aptus Pharma Ltd (APPL) and Cipla Ltd (CIPLA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Cipla Ltd leads APPL vs CIPLA on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
Valuation
How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has reduced debt.", "Company has a good return on equity (ROE) track record: 3 Years ROE 40.8%"]
- − ["Stock is trading at 18.2 times its book value", "Though the company is reporting repeated profits, it is not paying out dividend", "Debtor days have increased from 99.8 to 147 days.", "Working capital days have increased from 73.4 days to 117 days"]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.